ESR1 and breast carcinoma: A new phase III clinical trial (TROPiCS-02 study, NCT03901339), evaluating sacituzumab govitecan versus standard treatment in ER+/HER2- metastatic breast cancers, has also been initiated recently and is expected to provide data in the near future [34].